Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
SAN FRANCISCO, Dec. 22, 2016 -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the company will be participating in the upcoming 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
iRhythm’s management is scheduled to present on Wednesday, January 11, 2017 at 11:00am PT. Interested parties may access a webcast of the presentation on the “Investor Relations” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a commercial-stage digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients. The company’s platform, the Zio Service, has been provided to over 500,000 patients, accumulating more than 125 million hours of curated heartbeat data within iRhythm’s data repository.
Investor Relations Contact: Lynn Pieper Lewis or Leigh Salvo (415) 937-5404 [email protected] Media Contact Aaron Murphy (415) 229-3331 [email protected]
